LentiGlobin for Sickle Cell Disease Gene Therapy Overview

Gene therapy webcrop
DP, drug product; HSCs, hematopoietic stem cells; RBCs, red blood cells

Two Current Studies

  • HGB-206: A study evaluating the safety and efficacy of the LentiGlobin BB305 drug product in severe Sickle Cell Disease (open but closed to recruitment.) 
  • HGB210: Phase 3 HGB-210 study of LentiGlobin in patients with Sickle Cell Disease (coming soon.)